New paradigms in the treatment of low-risk thyroid cancer

Baidoun, Firas; Saad, Anas M.; Abdel‐Rahman, Omar

doi:10.1080/17446651.2020.1773802

Cited by 4 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thyroid cancer is the most common endocrine malignancy with an estimated 44,280 new cases and 2,200 deaths in the United States (US) alone in 2021 and 586,202 new cases and about 43,000 deaths worldwide in 2020. The majority of thyroid cancer cases diagnosed in the US are differentiated thyroid cancer (DTC) which include papillary, follicular and Hurthle cell carcinoma [1][2][3][4]. The widespread use of diagnostic modalities including ultrasonography and ne-needle aspiration (FNA) has led to a rapid increase of thyroid cancer incidence rate in the US and worldwide in the last few decades.…”

Section: Introductionmentioning

confidence: 99%

The Role of Surgery in Small Differentiated Thyroid Cancer

Baidoun

Merjaneh

Abdel‐Rahman

2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The Role of Surgery in Small Differentiated Thyroid Cancer

Baidoun

Merjaneh

Abdel‐Rahman

2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

The role of surgery in small differentiated thyroid cancer

Baidoun

Abdel‐Rahman²

2022

Endocrine

View full text Add to dashboard Cite

Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk

Grani

Lamartina

Alfó

et al. 2020

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Current guidelines recommend a selective use of radioiodine treatment (RAI) for papillary thyroid cancer (PTC). Objective This work aimed to determine how policy changes affect the use of RAI and the short-term outcomes of patients. Methods A retrospective analysis of longitudinal data was conducted in an academic referral center of patients with nonaggressive PTC variants; no extrathyroidal invasion or limited to soft tissues, no distant metastases, and 5 or fewer central-compartment cervical lymph node metastases. In cohort 1, standard treatments were total thyroidectomy and RAI (May 2005-June 2011); in cohort 2 decisions on RAI were deferred for approximately 12 months after surgery (July 2011-December 2018). Propensity score matching was used to adjust for sex, age, tumor size, lymph node status, and extrathyroidal extension. Intervention included immediate RAI or deferred choice. Main outcome measures were responses to initial treatment during 3 or more years of follow-up. Results In cohort 1, RAI was performed in 50 of 116 patients (51.7%), whereas in cohort 2, it was far less frequent: immediately in 10 of 156 (6.4%), and in 3 more patients after the first follow-up data. The frequencies of structural incomplete response were low (1%-3%), and there were no differences between the 2 cohorts at any follow-up visit. Cohort 2 patients had higher rates of “gray-zone responses” (biochemical incomplete or indeterminate response). Conclusion Selective use of RAI increases the rate of patients with “uncertain” status during early follow-up. The rate of structural incomplete responses remains low regardless of whether RAI is used immediately. Patients should be made aware of the advantages and drawbacks of omitting RAI.

show abstract

New paradigms in the treatment of low-risk thyroid cancer

Cited by 4 publications

References 97 publications

The Role of Surgery in Small Differentiated Thyroid Cancer

The Role of Surgery in Small Differentiated Thyroid Cancer

The role of surgery in small differentiated thyroid cancer

Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk

Contact Info

Product

Resources

About